

2018 Coronary Artery Disease Drug Development Pipeline Analysis Report- Companies, Drugs, Clinical Trials, Latest Developments in Coronary Artery Disease Market

<https://marketpublishers.com/r/2C7C2FEB25DEN.html>

Date: June 2018

Pages: 70

Price: US\$ 999.00 (Single User License)

ID: 2C7C2FEB25DEN

Abstracts

Coronary artery disease is a heart condition in which plaque piles up in arteries of a patient, which reduces the area for free flow of blood, thereby, causing angina or chest pain. This can eventually turn out to be a heart attack and arrhythmia. With an estimated 18 million population being affected in the US, Coronary artery diseases are among the most rapidly expanding disease in the US and world. Further, the US Coronary Heart disease market is sized at \$95 billion during 2017.

To assist researchers, investors and business development managers, VPA Research has come up with a comprehensive report on Coronary Artery Disease pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.

Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Coronary Artery Disease pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.

In addition to complete details of each product, the report provides key trends in Coronary Artery Disease pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.

Contents

1 TABLE OF CONTENTS

1.1 List of LIST OF FIGURES

1.2 List of Tables

2 CORONARY ARTERY DISEASE PIPELINE ANALYSIS

2.1 Disease and Pipeline Overview

2.2 Coronary Artery Disease Pipeline Snapshot

2.3 Coronary Artery Disease Pipeline by Phase

2.4 Coronary Artery Disease Pipeline by Company

2.5 Coronary Artery Disease Pipeline by Mechanism of Action

3 CORONARY ARTERY DISEASE- COMPANY WISE PIPELINE ANALYSIS

advanceCor GmbH

Angionetics Inc

AngioSoma Inc

APT Therapeutics Inc

Ascendia Pharmaceuticals LLC

AstraZeneca Plc

Bayer HealthCare Pharmaceuticals

Bio-Thera Solutions Ltd

Biscayne Pharmaceuticals Inc

Bracco Imaging S.p.A.

Capricor Therapeutics Inc

CardioVascular BioTherapeutics Inc

CSL Ltd

DalCor Pharmaceuticals Inc

Hemostemix Inc

Idorsia Ltd

Jaan Biotherapeutics LLC

LipimetiX Development Inc

MedImmune LLC

Pharmahungary

Proteon Therapeutics Inc

Recardio, Inc.

Resverlogix Corp
Servier Laboratories Limited
The Medicines Company
Vasade Biosciences
VESSL Therapeutics Ltd
ViroMed Co Ltd
XyloCor Therapeutics Inc
List Continues...

4 CORONARY ARTERY DISEASE R&D PIPELINE SNAPSHOTS

Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/ License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details

5 RECENT DEVELOPMENTS IN CORONARY ARTERY DISEASE PIPELINE

6 APPENDIX

6.1 About VPA Research
6.2 Sources and Research Methodology

List Of Figures

LIST OF FIGURES

Figure 1: Coronary Artery Disease Pipeline by Phase, H2- 2018

Figure 2: Coronary Artery Disease Pipeline by Companies, H2- 2018

Figure 3: Company Wise Pipeline Drug Phases, H2- 2018

Figure 4: Coronary Artery Disease Pipeline by Mechanism of Action, H2- 2018

Figure 5: Mechanism Wise Pipeline Drug Phases, H2- 2018

List Of Tables

LIST OF TABLES

- Coronary Artery Disease Pipeline by Phase, H2- 2018
- Coronary Artery Disease Pipeline by Companies, H2- 2018
- Coronary Artery Disease Pipeline by Mechanism of Action, H2- 2018
- Table 1: advanceCor GmbH Coronary Artery Disease Pipeline Drugs, H2- 2018
- Table 2: Angionetics Inc Coronary Artery Disease Pipeline Drugs, H2- 2018
- Table 3: AngioSoma Inc Coronary Artery Disease Pipeline Drugs, H2- 2018
- Table 4: APT Therapeutics Inc Coronary Artery Disease Pipeline Drugs, H2- 2018
- Table 5: Ascendia Pharmaceuticals LLC Coronary Artery Disease Pipeline Drugs, H2- 2018
- Table 6: AstraZeneca Plc Coronary Artery Disease Pipeline Drugs, H2- 2018
- Table 7: Bayer HealthCare Pharmaceuticals Coronary Artery Disease Pipeline Drugs, H2- 2018
- Table 8: Bio-Thera Solutions Ltd Coronary Artery Disease Pipeline Drugs, H2- 2018
- Table 9: Biscayne Pharmaceuticals Inc Coronary Artery Disease Pipeline Drugs, H2- 2018
- Table 10: Bracco Imaging S.p.A. Coronary Artery Disease Pipeline Drugs, H2- 2018
- Table 11: Capricor Therapeutics Inc Coronary Artery Disease Pipeline Drugs, H2- 2018
- Table 12: CardioVascular BioTherapeutics Inc Coronary Artery Disease Pipeline Drugs, H2- 2018
- Table 13: CSL Ltd Coronary Artery Disease Pipeline Drugs, H2- 2018
- Table 14: DalCor Pharmaceuticals Inc Coronary Artery Disease Pipeline Drugs, H2- 2018
- Table 15: Hemostemix Inc Coronary Artery Disease Pipeline Drugs, H2- 2018
- Table 16: Idorsia Ltd Coronary Artery Disease Pipeline Drugs, H2- 2018
- Table 17: Jaan Biotherapeutics LLC Coronary Artery Disease Pipeline Drugs, H2- 2018
- Table 18: LipimetiX Development Inc Coronary Artery Disease Pipeline Drugs, H2- 2018
- Table 19: MedImmune LLC Coronary Artery Disease Pipeline Drugs, H2- 2018
- Table 20: Pharmahungary Coronary Artery Disease Pipeline Drugs, H2- 2018
- Table 21: Proteon Therapeutics Inc Coronary Artery Disease Pipeline Drugs, H2- 2018
- Table 22: Recardio, Inc. Coronary Artery Disease Pipeline Drugs, H2- 2018
- Table 23: Resverlogix Corp Coronary Artery Disease Pipeline Drugs, H2- 2018
- Table 24: Servier Laboratories Limited Coronary Artery Disease Pipeline Drugs, H2- 2018
- Table 25: The Medicines Company Coronary Artery Disease Pipeline Drugs, H2- 2018

Table 26: Vasade Biosciences Coronary Artery Disease Pipeline Drugs, H2- 2018

Table 27: VESSL Therapeutics Ltd Coronary Artery Disease Pipeline Drugs, H2- 2018

Table 28: ViroMed Co Ltd Coronary Artery Disease Pipeline Drugs, H2- 2018

Table 29: XyloCor Therapeutics Inc Coronary Artery Disease Pipeline Drugs, H2- 2018

Table 30: List Continues... Coronary Artery Disease Pipeline Drugs, H2- 2018

I would like to order

Product name: 2018 Coronary Artery Disease Drug Development Pipeline Analysis Report- Companies, Drugs, Clinical Trials, Latest Developments in Coronary Artery Disease Market

Product link: <https://marketpublishers.com/r/2C7C2FEB25DEN.html>

Price: US\$ 999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/2C7C2FEB25DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

